NCT00845988

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders

Metabolic Effects of Switching to Aripiprazole in Patients With Bipolar Disorders Having Drug-induced Weight Gain

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 28 (actual)
• Sponsor: Seoul National University Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The primary goal of this study is to investigate metabolic changes and maintaining efficacy in stabilized patients with bipolar disorders who have pharmacologically induced weight gain.

Detailed description

* reduced treatment adherence due to metabolic side effects * suggested advantages of aripiprazole in metabolic profile over other antipsychotics or mood stabilizers * randomized trial of switch from previous drugs to aripiprazole

Conditions

• Bipolar Disorders
• Metabolic Complication

Interventions

Type	Name	Description
DRUG	aripiprazole	dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks

Timeline

• Start date: 2008-12-01
• Primary completion: 2012-03-01
• Completion: 2012-03-01
• First posted: 2009-02-18
• Last updated: 2013-12-05

Locations

1 site across 1 country: South Korea